Fortress Biotech, Inc.
FBIOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 18, 2026 | Industrial Alliance Securities | $5.00(+96%) | $2.55 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Feb 23, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 21, 2025 |
| Roth MKM | maintain | Buy | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 19, 2024 |
| Roth MKM | maintain | Buy | May 16, 2024 |
| Roth MKM | maintain | Buy | Nov 29, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Aug 15, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Aug 14, 2023 |
| Cantor Fitzgerald | maintain | Overweight | May 16, 2023 |
| Cantor Fitzgerald | maintain | Overweight | May 15, 2023 |
| B. Riley Securities | maintain | Buy | Jul 14, 2022 |
| B. Riley Securities | maintain | Buy | Jul 13, 2022 |
| Roth Capital | maintain | Buy | Apr 20, 2021 |
| Roth Capital | maintain | Buy | Apr 19, 2021 |
| Roth Capital | maintain | Buy | Oct 13, 2020 |
| Roth Capital | maintain | Buy | Oct 12, 2020 |
| HC Wainwright & Co. | maintain | Buy | Oct 12, 2020 |
| HC Wainwright & Co. | maintain | Buy | Oct 11, 2020 |
| B. Riley FBR | maintain | Buy | Mar 13, 2020 |
| B. Riley Securities | maintain | Buy | Mar 12, 2020 |
Earnings History
Next report: Nov 16, 2026 · EPS est. $-0.27| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.08 | $-0.20 | $18.7M | $18.3M |
| May 14, 2026 | $2.82 | $-0.22 | $16.0M | $16.3M |
| Mar 31, 2026 | $-0.21 | $0.42 | $16.1M | $26.2M |
| Nov 14, 2025 | $0.11 | $-0.43 | $17.6M | $21.0M |
| Aug 14, 2025 | $-0.46 | $-0.31 | $16.4M | $21.0M |
| May 15, 2025 | $-0.48 | $-0.44 | $13.1M | $11.6M |
| Mar 31, 2025 | $-0.26 | $-0.79 | $15.1M | $14.6M |
| Nov 14, 2024 | $-0.76 | $-0.27 | $14.6M | $15.6M |
News
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 12, 2026 at 4:30 p.m. ET
Fortress Biotech (NASDAQ: FBIO - Get Free Report) and Johnson and Johnson (NYSE: JNJ - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations. Volatility and Risk Fortress Biotech has a
RYTHM (NASDAQ: RYM - Get Free Report) and Fortress Biotech (NASDAQ: FBIO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation. Valuation and Earnings This table compares RYTHM and
SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The prese…
Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO ® and UNLOXCYT ™ MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative bioph…
Fortress Biotech, Inc. (FBIO) Q2 2026 Earnings Call Transcript